Stock Scorecard



Stock Summary for BioVie Inc (BIVI) - $3.11 as of 9/28/2023 3:28:59 PM EST

Total Score

9 out of 29

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BIVI

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BIVI

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BIVI

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2

Bonus Criteria for BIVI

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Latest News for for BIVI

BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation 9/19/2023 12:45:00 PM
BioVie Hosting Virtual KOL Event on NE3107 in Alzheimer's Disease Today, September 7, 2023 - BioVie ( NASDAQ:BIVI ) 9/7/2023 12:00:00 PM
Top 5 Health Care Stocks That May Explode In Q3 - BioVie ( NASDAQ:BIVI ) , Galera Therapeutics ( NASDAQ:GRTX ) 9/6/2023 11:36:00 AM
BioVie to Host Virtual KOL Event on NE3107 in Alzheimer's Disease on September 7, 2023 8/31/2023 12:00:00 PM
Down -26.93% in 4 Weeks, Here's Why BioVie Inc. ( BIVI ) Looks Ripe for a Turnaround 8/30/2023 1:35:00 PM
Down -29.2% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. ( BIVI ) 8/28/2023 1:35:00 PM
BioVie Presents Data for NE3107 at 2023 International Congress of Parkinson's Disease and Movement Disorders 8/28/2023 12:00:00 PM
Down -23.45% in 4 Weeks, Here's Why You Should You Buy the Dip in BioVie Inc. ( BIVI ) 8/24/2023 1:35:00 PM
Medical Second Opinion Global Market to Register Stunning Growth at a CAGR of ~17% by 2028 | DelveInsight 8/21/2023 9:01:00 PM
Dementia Market to Grow Rapidly, Estimates DelveInsight | Key Companies Active in the Market - Pfizer, Eli Lilly and Company, Janssen, Merck, BioVie, Biogen, Vivoryon, Sage, Alnylam, BioXcel, EIP, Otsuka, Alector, Transposon 7/26/2023 9:01:00 PM

Financial Details for BIVI

Company Overview

Ticker BIVI
Company Name BioVie Inc
Country USA
Description BioVie Inc., a clinical-stage biotechnology company, is dedicated to the discovery, development, and commercialization of drug therapies in the United States. The company is headquartered in Santa Monica, California.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2023
Next Earnings Date 11/1/2023

Stock Price History

Last Day Price 3.11
Last Day Price Updated 9/28/2023 3:28:59 PM EST
Last Day Volume 0
Average Daily Volume 228,765
52-Week High 14.38
52-Week Low 2.28
Last Price to 52 Week Low 36.40 %

Valuation Measures

Trailing PE N/A
Industry PE 43.96
Sector PE 47.89
5-Year Average PE -3.95
Free Cash Flow Ratio 5.87
Industry Free Cash Flow Ratio 12.58
Sector Free Cash Flow Ratio 31.90
Current Ratio Most Recent Quarter 2.35
Total Cash Per Share 0.53
Book Value Per Share Most Recent Quarter 0.42
Price to Book Ratio 63.00
Industry Price to Book Ratio 4.72
Sector Price to Book Ratio 21.80
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 5.61
Sector Price to Sales Ratio Twelve Trailing Months 3.72

Share Statistics

Total Shares Outstanding 36,803,800
Market Capitalization 114,459,818
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Dividend Aristocrat? False
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00 %
5-Year Dividend Payments Count 0
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00 %
Annual Earnings Growth -92.67 %
Reported EPS 12 Trailing Months -1.94
Reported EPS Past Year -1.56
Reported EPS Prior Year -1.12
Net Income Twelve Trailing Months -50,255,815
Net Income Past Year -50,255,815
Net Income Prior Year -26,084,468
Quarterly Revenue Growth YOY 0.00 %
5-Year Revenue Growth 104.51 %

Balance Sheet

Total Cash Most Recent Quarter 19,460,883
Total Cash Past Year 19,460,883
Total Cash Prior Year 18,641,716
Net Cash Position Most Recent Quarter 4,278,539
Net Cash Position Past Year 4,278,539
Long Term Debt Past Year 15,182,344
Long Term Debt Prior Year 15,850,000
Total Debt Most Recent Quarter 15,182,344
Equity to Debt Ratio Past Year 0.50
Equity to Debt Ratio Most Recent Quarter 0.50
Total Stockholder Equity Past Year 15,340,286
Total Stockholder Equity Prior Year 3,670,935
Total Stockholder Equity Most Recent Quarter 15,340,286

Options

Put/Call Ratio 0.00
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.17
MACD Signal -0.21
20-Day Bollinger Lower Band 2.13
20-Day Bollinger Middle Band 4.54
20-Day Bollinger Upper Band 6.95
Beta 2.18
RSI 44.76
50-Day SMA 5.85
200-Day SMA 8.56

System

Modified 9/28/2023 7:25:14 PM EST